Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Calvez

Showing results (281-290 of 329) with videos related to

Pageof 33
Sort By:
BMC Infectious Diseases|March 28, 2025
Seroprevalence of anti-SARS-CoV-2 IgG antibodies among children attending the pediatric hospital in Bamako, Mali (BamaCoV-Kids Study)Almoustapha Issiaka Maiga, Amadou Kodio, Salimata Alou Ouedraogo, et al.
Pharmacotherapy|March 1, 2019
Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL StudyMinh Patrick Lê, Marc-Antoine Valantin, Lambert Assoumou, et al.
The Journal of Infectious Diseases|June 26, 2009
Predictive value of HIV-1 genotypic resistance test interpretation algorithmsSoo-Yon Rhee, W Jeffrey Fessel, Tommy F Liu, et al.
Frontiers in Immunology|December 6, 2021
XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes VariantsBernard Vanhove, Stéphane Marot, Ray T So, et al.
Frontiers in Immunology|May 15, 2023
Corrigendum: XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2 spike receptor-binding domain, targets multiple epitopes and broadly neutralizes variantsBernard Vanhove, Stéphane Marot, Ray T So, et al.
Chemical Biology & Drug Design|August 14, 2018
New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T)Lydia Pouga, Maria Mercedes Santoro, Charlotte Charpentier, et al.
AIDS (London, England)|June 22, 2022
High seroconversion rate and SARS-CoV-2 Delta neutralization in people with HIV vaccinated with BNT162b2Valérie Pourcher, Lisa Belin, Cathia Soulie, et al.
Antiviral Therapy|January 24, 2012
Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimenAnne-Genevieve Marcelin, Diane Descamps, Catherine Tamalet, et al.
AIDS Research and Human Retroviruses|July 25, 2012
Transmitted antiretroviral drug resistance in newly HIV-infected and untreated patients in Ségou and Bamako, MaliAlmoustapha Issiaka Maiga, Djeneba Bocar Fofana, Aichatou Chehy Maiga, et al.
Chemmedchem|September 29, 2011
Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirineStefano Alcaro, Claudia Alteri, Anna Artese, et al.
Pageof 33

Showing results (281-290 of 329) with videos related to

Sort By:
Pageof 33
BMC Infectious Diseases|March 28, 2025
Seroprevalence of anti-SARS-CoV-2 IgG antibodies among children attending the pediatric hospital in Bamako, Mali (BamaCoV-Kids Study)Almoustapha Issiaka Maiga, Amadou Kodio, Salimata Alou Ouedraogo, et al.
Pharmacotherapy|March 1, 2019
Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL StudyMinh Patrick Lê, Marc-Antoine Valantin, Lambert Assoumou, et al.
The Journal of Infectious Diseases|June 26, 2009
Predictive value of HIV-1 genotypic resistance test interpretation algorithmsSoo-Yon Rhee, W Jeffrey Fessel, Tommy F Liu, et al.
Frontiers in Immunology|December 6, 2021
XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes VariantsBernard Vanhove, Stéphane Marot, Ray T So, et al.
Frontiers in Immunology|May 15, 2023
Corrigendum: XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2 spike receptor-binding domain, targets multiple epitopes and broadly neutralizes variantsBernard Vanhove, Stéphane Marot, Ray T So, et al.
Chemical Biology & Drug Design|August 14, 2018
New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T)Lydia Pouga, Maria Mercedes Santoro, Charlotte Charpentier, et al.
AIDS (London, England)|June 22, 2022
High seroconversion rate and SARS-CoV-2 Delta neutralization in people with HIV vaccinated with BNT162b2Valérie Pourcher, Lisa Belin, Cathia Soulie, et al.
Antiviral Therapy|January 24, 2012
Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimenAnne-Genevieve Marcelin, Diane Descamps, Catherine Tamalet, et al.
AIDS Research and Human Retroviruses|July 25, 2012
Transmitted antiretroviral drug resistance in newly HIV-infected and untreated patients in Ségou and Bamako, MaliAlmoustapha Issiaka Maiga, Djeneba Bocar Fofana, Aichatou Chehy Maiga, et al.
Chemmedchem|September 29, 2011
Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirineStefano Alcaro, Claudia Alteri, Anna Artese, et al.
Pageof 33